Univ. Klinik für Innere Medizin / Gem. Einrichtung für Intensiv- und Notfallmedizin/GE Medizinische Universität Innsbruck
Welcome,         Profile    Billing    Logout  
 2 Trials 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
JOANNIDIS, Michael
VITDALIZE, NCT03188796 / 2016-002460-13: The Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

Recruiting
3
2400
Europe
Cholecalciferol, Vitamin D3, Placebo
Medical University of Graz, Medical University of Vienna, Hospital Barmherzige Brüder St. Veit, Klinikum Klagenfurt am Wörthersee, Johannes Kepler University of Linz, Krankenhaus Barmherzige Schwestern Linz, Barmherzige Brüder Vienna, Erasme University Hospital, The Queen Elizabeth Hospital, Goethe University, Kages, KABEG Management, Centre Hospitalier Régional de la Citadelle, Centre Hospitalier Universitaire de Charleroi, Centre Hospitalier Universitaire Mons, Wuerzburg University Hospital, Royal Bolton Hospital NHS Foundation Trust, Heartlands Hospital, Royal Oldham Hospital, East Lancashire Hospitals NHS Trust, University of Plymouth, The Royal Victoria Hospital, Belfast, Great Western Hospital, Mid Yorkshire Teaching NHS Trust, Musgrove Park Hospital, Scunthorpe General Hospital, Guy's and St Thomas' NHS Foundation Trust, Nottingham University Hospitals, Hospital Barmherzige Brüder Graz, University Hospital Kiel, University Hospital, Bonn, Johannes Gutenberg University Mainz, University Hospital, Essen, Klinikum rechts der Isar der TUM, Landeskrankenhaus Villach
Critical Illness, Vitamin D Deficiency, Covid19
12/26
03/27
NCT04071171 / 2019-001262-15: Comparison of Biphozyl® and Phoxilium® as a Replacement Fluid During CVVH for AKI in Adults and Their Effects on pH-, Bicarbonate-levels and Respiratory Situation

Completed
2
88
Europe
CVVH with Phoxilium® in the first 48h after randomization, CVVH with Biphozyl® in the first 48h after randomization, CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®), CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®)
Medical University Innsbruck
Critically Ill, Acute Kidney Injury, Renal Replacement Therapy, Continuous Renal Replacement Therapy, Continuous Veno-Venous Hemofiltration, Replacement Fluid, Phoxilium, Biphozyl, Anticoagulation, Regional Citrate Anticoagulation
11/23
03/24
NCT03567577 / 2017-003855-47: Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

Recruiting
2
95
Europe
Solnatide 25 mg powder for reconstitution for solution for inhalation, AP301, 0.9% Saline Solution
Apeptico Forschung und Entwicklung GmbH
ARDS
12/24
12/24
Fischer, Bernhard
NCT03567577 / 2017-003855-47: Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

Recruiting
2
95
Europe
Solnatide 25 mg powder for reconstitution for solution for inhalation, AP301, 0.9% Saline Solution
Apeptico Forschung und Entwicklung GmbH
ARDS
12/24
12/24

Download Options